Canada markets closed

Cingulate Inc. (CINGW)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.0200+0.0058 (+40.85%)
At close: 09:30AM EST
Full screen
Trade prices are not sourced from all markets
Previous Close0.0142
Open0.0200
Bid0.0134 x 4000
Ask0.0200 x 800
Day's Range0.0200 - 0.0200
52 Week Range0.0200 - 0.0200
Volume3,002
Avg. VolumeN/A
Market CapN/A
Beta (5Y Monthly)-0.64
PE Ratio (TTM)N/A
EPS (TTM)-1.7320
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors

    Announcement Follows Recent Public Offering and Successful Capital Raising ActivityKANSAS CITY, Kan., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that it has appointed three new directors to its board: Jay Roberts, Bryan Lawrence, and Jeff Ervin. The appointment of t

  • GlobeNewswire

    Cingulate Announces Closing of $7.5 Million Public Offering

    KANSAS CITY, Kan., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the closing of its public offering of an aggregate of 3,750,000 shares of its common stock (or common stock equivalents in lieu thereof), Series A warrant

  • GlobeNewswire

    Cingulate Announces Pricing of $7.5 Million Public Offering

    KANSAS CITY, Kan., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the pricing of its public offering of an aggregate of 3,750,000 shares of its common stock (or common stock equivalents in lieu thereof), Series A warrant